European Commission approves RINVOQ for severe alopecia areata

AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers

Incyte's Opzelura approved in European Union for moderate atopic dermatitis

Synlogic and Caldera Therapeutics agree merger

RTW Biotech portfolio company Yarrow Bioscience completes merger

Hemogenyx partners with Lithuanian cancer centre on HG-CT-1 research and clinical programme

Evinova and Merck KGaA partner to accelerate AI-driven clinical development

WuXi Biologics gains FTSE4Good recognition for sixth consecutive year

Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184

DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development

AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance

CSL reports positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children with HAE

Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101

Harbour BioMed and Sinopharm establish innovation R&D consortium

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102